<DOC>
	<DOCNO>NCT00935545</DOCNO>
	<brief_summary>This open-label , single arm study evaluate multi-peptide ( tumor-associated antigen ) /Montanide vaccine patient &lt; 21 year age recurrent refractory CNS tumor . The study primarily evaluate safety regimen . Secondarily , immunogenicity anti-tumor effect assess . The primary aim evaluate safety subcutaneous injection tumor associate antigen ( TAA ) mix Montanide ISA-51VG patient recurrent refractory brain tumor . The secondary aim evaluate cellular immune response induce patient subcutaneous injection TAA mixed Montanide ISA-51VG document tumor response patient measurable disease time progression patient without measurable disease follow subcutaneous injection TAA mixed Montanide ISA-51VG .</brief_summary>
	<brief_title>Study Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide Patients With CNS Tumors</brief_title>
	<detailed_description />
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients primary central nervous system tumor recurrent refractory standard therapy . Patients recurrent tumor refractory anaplastic astrocytoma , glioblastoma multiforme medulloblastoma must fail available second line therapy consider standard care prior inclusion study . 2 . Patients tumor histology previously show express least one tumor associate antigen ( TRP2 , gp100 , EphA2 Her2 ) eligible . Patients whose tumor show express least one antigens also eligible . 3 . Patients must HLA A*0201 positive . 4 . Age &lt; 21 year 5 . Patients must weigh &gt; 15kg due amount blood require immune function study . 6 . Lansky performance status Karnofsky performance status &gt; 50 . Patients unable walk paralysis wheelchair , consider ambulatory purpose assess performance score . 7 . Adequate organ function : Hematologic : WBC &gt; 1000/mm3 Absolute lymphocyte count &gt; 500 Hemoglobin &gt; 9 gm/dl ( may transfuse achieve adequate hemoglobin level ) Platelet count &gt; 50,000/mm3 INR PTT &lt; 1.5 x upper limit normal Hepatic : AST/ALT &lt; 2 x upper limit institutional normal Total bilirubin &lt; 1.5 x upper limit institutional normal Renal : Serum creatinine &lt; upper limit normal patient 's age 8 . Life expectancy &gt; 3 month 9 . Patients must fully recover previous surgery , chemotherapy , radiotherapy biologic therapy . No chemotherapy , radiation therapy immunotherapy within 4 week prior first dose study agent ( 6 week nitrosureas ) 10 . Measurable disease require . 11 . Informed consent must sign patient legal representative . Exclusion Criteria 1 . Serious illness , eg , uncontrolled infection require antibiotic . 2 . History immunodeficiency disease ( HIV ) autoimmune disease except vitiligo . 3 . Concomitant treatment systemic corticosteroid great physiologic dos . Topical ( propose vaccination site ) inhalational steroid permit . 4 . Participation clinical trial involve another investigational agent within 4 week prior first dose study agent . 5 . Pregnant lactate woman permit . 6 . Women childbearing potential use medically acceptable mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Brain Tumors</keyword>
	<keyword>High Grade</keyword>
	<keyword>CNS</keyword>
</DOC>